共 63 条
[1]
Ferreri AJM(2017)Therapy of primary CNS lymphoma: role of intensity, radiation, and novel agents Hematol Am Soc Hematol Educ Program 2017 565-577
[2]
Grommes C(2017)Primary CNS lymphoma J Clin Oncol 35 2410-2418
[3]
DeAngelis LM(2009)High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial Lancet 374 1512-1520
[4]
Ferreri AJ(2002)Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: radiation therapy oncology group study 93–10 J Clin Oncol 20 4643-4648
[5]
Reni M(2016)Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the international extranodal lymphoma study group-32 (IELSG32) phase 2 trial Lancet Haematol 3 e217-e227
[6]
Foppoli M(2006)Primary central nervous system lymphoma: the Memorial Sloan-Kettering cancer center prognostic model J Clin Oncol 24 5711-5715
[7]
Ferreri AJ(2003)Prognostic scoring system for primary CNS lymphomas: the international extranodal lymphoma study group experience J Clin Oncol 21 266-272
[8]
Cwynarski K(2005)Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma J Clin Oncol 23 5034-5043
[9]
Pulczynski E(2016)Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network Neuro Oncol 18 1297-1303
[10]
Abrey LE(2000)Treatment for primary CNS lymphoma: the next step J Clin Oncol 18 3144-3150